Pension plans resilient in the face of global economic volatility Français
Due to the announcement of US tariffs, the report also provided an estimate for the first week of April 2025, projecting that the median solvency ratio likely declined further, by approximately five percentage points from the end of Q1, driven by adverse market conditions.
Despite this decrease, the vast majority of pension plans continued to demonstrate resilience, with funding levels remaining healthy amidst these economic and market challenges.
"While we've seen a decline in the solvency ratio over the past few months, pension plans remain resilient," said Andrew Fung, FSRA Executive Vice-President, Pensions. "However, with this global trade war and ongoing economic uncertainty, it's critical for plan administrators to proactively manage risk and regularly reassess their investment strategies to ensure long-term sustainability."
FSRA recommends that pension plans use stress testing, modeling, and other analytical tools to evaluate potential vulnerabilities and strengthen financial resilience.
FSRA releases its solvency report each quarter to assess the financial health of Ontario defined benefit pension plans. The report provides timely information to plan members about the performance of their plan and the state of the economy both nationally and internationally.
FSRA continues to work on behalf of all stakeholders, including consumers and pension plan members, to ensure financial safety, fairness, and choice for everyone.
Learn more at www.fsrao.ca.
FOR MEDIA INQUIRIES:
Ashley Legassic
Sr. Media Relations and Digital Officer
Financial Services Regulatory Authority
C: 647-719-8426
Email: [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
19 minutes ago
- Cision Canada
Microland Recognized as a Leader in ISG Provider Lens™ 2025 for Aerospace and Defense Services and Solutions (U.S.)
BENGALURU, India, July 23, 2025 /CNW/ -- Microland, an AI-First, Platform-Led Tech Infrastructure Services Company, has been named a Leader in the Technology Transformation and Consulting – Mid-size IT Providers/Specialists quadrant in the ISG Provider Lens™ 2025 report for the U.S. Aerospace and Defense (A&D) sector. As the A&D industry evolves amid shifting geopolitical landscapes, rapid technological advancements, and stringent security and regulatory demands, mid-size IT providers like Microland play a crucial role in helping enterprises modernize legacy systems, strengthen supply chain resilience, and gain AI-driven operational efficiencies. "Microland specializes in infrastructure managed services tailored for the A&D industry. The company guarantees operational efficiency and regulatory compliance, ensuring assets' high availability through predictive intelligence and automation," said Swadhin Pradhan, Assistant Director and Principal Analyst at ISG. " This recognition affirms Microland's AI-First vision and Platform-led value creation. With Intelligeni-Genie, our Agentic AI ITOps platform, we enable enterprises to deliver unfaltering user experiences built on a robust backbone of intelligent, secure, and resilient tech infrastructure," said Meenu Bagla, Chief Marketing Officer, Microland. Manjanath Nayak, Global Chief Delivery Officer and Co-Lead Americas, added, "This recognition reflects Microland's commitment to addressing the unique challenges of the A&D sector. From ITAR-compliant hybrid cloud transformations to predictive, resilient operations, our innovative platform-driven approach is helping A&D enterprises navigate increasing complexity with confidence and measurable outcomes." About Microland: Microland is the world's leading AI-First, Platform-Led Tech Infrastructure Solutions Company, enabling intelligent, resilient, and future-ready enterprise operations for over 100 global customers. With a sharp focus on customer centricity, delivery excellence, and innovation, Microland is a trusted partner in technology transformation. Backed by more than 35 years of proven expertise across digital networks, cloud and data centers, digital workplace, and cybersecurity — and supported by a robust global delivery model — Microland empowers operations in over 100 countries. Microland's award-winning AIOps platform, Intelligeni, powered by its Agentic AI engine, Intelligeni Genie, is redefining the future of autonomous enterprise operations.
Cision Canada
19 minutes ago
- Cision Canada
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds
VANCOUVER, BC, July 23, 2025 /CNW/ -- USA News Group News Commentary – Cancer diagnoses are climbing fastest among younger women, sparking alarm that looming cuts to U.S. research budgets could stall progress in prevention and treatment. Adding to the strain, federal and state regulators are re‑examining mRNA vaccines, creating a cloud of uncertainty over future cancer‑funding priorities. Yet even amid this policy turbulence, a new wave of oncology innovators is lining up near‑term milestones that could reshape the landscape—led by Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Cue Biopharma, Inc. (NASDAQ: CUE), Verastem, Inc. (NASDAQ: VSTM), Allogene Therapeutics, Inc. (NASDAQ: ALLO), and Perspective Therapeutics, Inc. (NYSE-American: CATX). While regulatory red tape tightens, surging diagnoses of colorectal and other GI cancers in young people demand quicker innovation in oncology. Forecasts suggest worldwide cancer‑drug revenues could blow past US$900 billion by 2034. Within that, next‑gen therapies built on precision techniques are slated to reach US$175.2 billion, advancing at a brisk 7.35% annual clip. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) recently held a well‑attended key opinion leader (KOL) webinar where pancreatic and gastrointestinal cancer specialists dissected pelareorep's clinical history, its biomarker data package, and where the oncolytic virus could slot into evolving chemotherapy and immunotherapy regimens. "I want to thank our esteemed panel of oncologists for their meaningful contributions to our KOL event," said Jared Kelly, CEO of Oncolytics. "Their insights underscore a critical and timely message: pelareorep is a compelling immunotherapy platform that is well situated for combination strategies and a highly differentiated asset for pharma partners looking to expand or establish leadership in GI oncology. We are committed to moving forward aggressively toward registrational development while engaging with partners who share our vision of transforming outcomes in these difficult-to-treat cancers." The panel revisited survival gains in metastatic pancreatic ductal adenocarcinoma (mPDAC), reviewed translational evidence of "cold‑to‑hot" tumor conversion, and outlined next steps for a registration-enabling study. Management said feedback from the discussion would inform both upcoming trial designs and partnering talks now underway. The event came on the heels of Oncolytics having rolled out an expanded translational‑data review that tightened the scientific case for pelareorep, an intravenously delivered oncolytic reovirus. Renewed analyses from the GOBLET gastrointestinal cancer study and the AWARE‑1 breast cancer study confirmed that the virus replicates inside tumors, switches on interferon signaling in the immune system, and draws tumor‑infiltrating lymphocytes into the tumor microenvironment. "This robust data set, amassed from several studies in cancers that have historically resisted immunotherapeutic approaches, provides definitive validation of pelareorep's immune-mediated mechanism of action," said Dr. Thomas Heineman, Chief Medical Officer of Oncolytics. "We observed tumor biopsy-confirmed virus replication, immune cell activation, and the recruitment of cytotoxic T cells into the TME – all consistent with the durable responses observed in patients with metastatic PDAC and HR+/HER2- breast cancer who were treated with pelareorep." Investigators also recorded higher PD‑L1 expression and tracked newly expanded cytotoxic T‑cell clones in blood samples that matched those inside shrinking lesions—molecular fingerprints that point to stronger responses when pelareorep is combined with standard-of-care treatments and checkpoint inhibitors. "The collection of data here show that pelareorep works how a cancer immunotherapy should work," said Jared Kelly, CEO of Oncolytics. "Pelareorep is a versatile product candidate with strong platform potential to enhance immunological responses in multiple indications, including hard-to-treat cancers. Such compelling findings should be exciting to strategic partners focused on finding a platform immunotherapy in large indications with high unmet medical needs." Clinical outcomes already hint at real‑world benefit. In more than 100 first‑line mPDAC patients, pelareorep‑based regimens achieved a 21.9% two‑year overall‑survival rate versus a 9.2% historical benchmark. A separate single‑arm study that paired pelareorep with chemotherapy and a checkpoint blocker produced a 62% objective‑response rate—especially notable given that no checkpoint therapy is approved in this cancer today. In hormone‑receptor‑positive, HER2‑negative metastatic breast cancer (HR+/HER2‑ mBC), two randomized trials added more than ten months of median overall survival, while BRACELET‑1 nearly doubled median progression‑free survival to 12.1 months compared with 6.4 months for control patients. To steer these data toward value‑creating deals and late‑stage trials, the company strengthened its leadership earlier this year by appointing industry veteran Jared Kelly as CEO and naming Andrew Aromando Chief Business Officer. The duo previously helped guide Ambrx Biopharma into a US$2 billion sale to Johnson & Johnson, experience the board believes will support capital‑efficient development and strategic partnering for pelareorep. "Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications," said Kelly. "With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy." As CBO, Aromando is now leading global business development and helping shape the company's corporate, clinical, and regulatory strategies. The leadership tandem is expected to prioritize partnering and expansion opportunities while preserving capital efficiency—a strategy well-suited for pelareorep's growing clinical profile. "I'm thrilled to join Oncolytics at such a pivotal moment in its evolution," said Aromando. "With promising data in difficult-to-treat cancers and a compelling body of clinical evidence in over 1,100 patients, I believe the Company is uniquely positioned to deliver meaningful value to patients and other stakeholders in the near term." Pelareorep currently holds FDA Fast Track designations in mPDAC (pancreatic cancer) and HR+/HER2‑ mBC (breast cancer), along with Orphan‑Drug status for pancreatic cancer in the United States and Europe. With mechanistic proof, survival data that outperform historical controls, and fresh validation from the recent KOL event, Oncolytics Biotech is aligning its clinical, regulatory, and business strategies to move pelareorep into registration‑enabling trials and position it as a backbone immunotherapy across solid tumors. In other recent industry developments and happenings in the market include: Cue Biopharma, Inc. (NASDAQ: CUE) recently reported that adding CUE‑101 to pembrolizumab produced a 50% overall response rate in patients with recurrent/metastatic HPV‑positive head and neck cancer who had a combined positive score (CPS) ≥ 1, including the same 50% response in those with low CPS 1–19. The regimen has now generated two complete responses, an 88% 12‑month overall survival rate, and a median overall survival of 32 months, handily outperforming historical pembrolizumab data. "The culmination of maturing data further support our conviction that CUE-101, representative of our approach with the CUE-100 series, demonstrates a potential breakthrough therapeutic approach for establishing a new standard of care," said Dan Passeri, CEO of Cue Biopharma. "With this maturing data, we are further emboldened in our conviction that our Immuno-STAT ® platform represents transformative potential for selectively modulating the patient's immune system." Verastem, Inc. (NASDAQ: VSTM) recently published Phase 2 RAMP 201 results in the Journal of Clinical Oncology, showing avutometinib + defactinib delivered a 31% confirmed overall response rate in recurrent low‑grade serous ovarian cancer, rising to 44% in KRAS‑mutant tumors. "The publication of the primary analysis of the RAMP 201 study in recurrent low-grade serous ovarian cancer in the Journal of Clinical Oncology reflects the meaningful clinical advancement demonstrated by the combination of avutometinib plus defactinib for patients with recurrent low-grade serous ovarian cancer," said John Hayslip, M.D., Chief Medical Officer at Verastem Oncology. "The findings supported the recent FDA approval of the combination in KRAS-mutated recurrent low-grade serous ovarian cancer and our ongoing global Phase 3 RAMP 301 trial of the combination in recurrent low-grade serous ovarian cancer with and without a KRAS mutation." Median progression‑free survival reached 12.9 months overall and 31.0 months in the KRAS‑mutant subgroup, with 82% of patients experiencing some tumor shrinkage regardless of mutation status. Back in June, Allogene Therapeutics, Inc. (NASDAQ: ALLO) presented updated Phase 1 TRAVERSE data showing a single dose of ALLO‑316 achieved a 31% confirmed response rate in heavily pre‑treated renal cell carcinoma patients whose tumors expressed CD70 in ≥ 50 % of cells. "ALLO-316 is showing clear evidence of targeted antitumor activity in patients who had failed most or all approved therapies for advanced or metastatic renal cell carcinoma," said Zachary Roberts, M.D., Ph.D., EVP, Research and Development and Chief Medical Officer at Allogene. "Our proprietary Dagger technology allows the use of a standard cyclophosphamide and fludarabine-based lymphodepletion regimen with a single dose of ALLO-316. Strong CAR T-cell kinetics and extensive infiltration of tumor tissue by CAR T cells are combining to generate deep and durable remissions. These are results that were previously considered out of reach for patients with advanced solid tumors." Four of five responders remain in remission—including one lasting more than 12 months—while safety remained manageable with no graft‑versus‑host disease observed. Investigators say the results highlight allogeneic CAR T's potential in solid tumors and justify continued expansion of the study. Perspective Therapeutics, Inc. (NYSE-American: CATX) recently began recruiting the third dose‑escalation cohort of its Phase 1/2a trial testing [²¹²Pb]VMT‑α‑NET in unresectable or metastatic somatostatin receptor 2 (SSTR2)‑positive neuroendocrine tumors, raising the fixed dose by 20% to 6 mCi. Earlier cohorts showed anti‑tumor activity with mostly low‑grade adverse events, prompting FDA alignment to explore whether the higher dose can further enhance efficacy. "We are excited to start exploring a higher dose level of VMT-α-NET after successfully completing an interaction with the FDA that was agreed prior to commencement of this trial," commented Markus Puhlmann, Chief Medical Officer of Perspective. "We are encouraged by the overall clinical profile observed at the second dose level of VMT-α-NET—including evidence of anti-tumor activity and primarily low-grade adverse events—and we believe it is important to assess whether a higher dose could further improve the therapeutic profile." The company plans additional safety and efficacy readouts, including dosimetry analyses, at scientific meetings in 2H 2025. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Cision Canada
19 minutes ago
- Cision Canada
Neutrinos Launches AI Agent Library
Enterprise-ready library of 50+ AI agents purpose-built for insurance industry complexities NEW YORK and SINGAPORE, July 23, 2025 /CNW/ -- Neutrinos, a leader in AI-powered intelligent automation for insurers, today announced the release of its AI Agent Library, designed to help insurers operationalize artificial intelligence across claims, underwriting, servicing, and distribution. Neutrinos supports insurers through the entire implementation journey, helping discover opportunities for agent adoption, design multi-agent workflows, build and integrate agents, and scale AI deployments with governance and observability. Delivered through the Neutrinos intelligent automation platform, the library enables agentic AI orchestration at scale. "For insurers looking to get started with agentic AI, this library delivers a fast, scalable, frictionless on-ramp," said Samik Ghosh, CEO and Co-Founder of Neutrinos. "Whether these are your first AI agents or you've already built some in-house or with other partners, the Neutrinos platform works alongside them. This library of agents reflects real-world insurance use cases and gives teams a practical, enterprise-grade foundation to deploy context-aware, governed AI without starting from scratch." Neutrinos AI Agent Library includes purpose-built models for insurance value streams across: Claims Automation: Deploy AI agents to orchestrate intake, verify claims data, and support adjudicators with context-aware decisions. Underwriting & Risk Assessment: Model risk, analyze documents, and recommend next best actions. Fraud Detection & Adjudication Support: Detect anomalies, validate evidence, and flag risk signals in real time. Customer Communication & Engagement: Support context-aware interactions across the policyholder lifecycle. Medical & Document Intelligence: Classify, extract, and analyze unstructured data across both underwriting and claims processes. Distribution Support & Compliance: Support case collaboration, agent oversight, and audit-readiness. "Insurers can introduce AI agents at any point in the business process, automating manual tasks or accelerating time to value, with seamless handshakes to legacy or modern platforms, minimizing disruption to existing systems," added Ghosh. To learn more or schedule a demo, contact Neutrinos here. About Neutrinos: Neutrinos is the leading AI-powered intelligent automation platform purpose-built for the insurance industry. At the core of our offering is the industry's most advanced agentic AI composer and orchestrator, designed specifically to automate and optimize complex, end-to-end insurance processes. From underwriting and claims to distribution, our platform empowers insurers with deep domain expertise, intelligent automation, and pre-built accelerators to drive faster innovation, operational efficiency, and seamless omni-channel experiences. Learn more at and follow Neutrinos on LinkedIn.
